Precision Biosciences (DTIL) Total Non-Current Liabilities (2020 - 2026)

Precision Biosciences (DTIL) has 7 years of Total Non-Current Liabilities data on file, last reported at $45.0 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 30.87% year-over-year to $45.0 million in Q1 2026; TTM through Mar 2026 was $45.0 million, a 30.87% decrease from a year earlier, with the FY2025 full-year figure at $46.5 million, down 33.61% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $45.0 million, down from $46.5 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for DTIL reached as high as $187.1 million in Q3 2022 and fell as low as $45.0 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $110.4 million across 5 years, with a median of $111.7 million in 2022.
• Across the five-year window, Total Non-Current Liabilities jumped 61.66% in 2022 and plunged 50.28% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $177.5 million in 2022, then retreated by 20.7% to $140.8 million in 2023, then plunged by 50.28% to $70.0 million in 2024, then tumbled by 33.61% to $46.5 million in 2025, then declined by 3.2% to $45.0 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $45.0 million in Q1 2026, $46.5 million in Q4 2025, and $76.6 million in Q3 2025.